Investigational drug may offer new treatment option for patients with lung and kidney cancer

Pegilodecakin, a first-in-class drug currently in clinical trials, has shown positive safety results and may offer a potential new treatment avenue for patients with non-small cell lung cancer (NSCLC) and kidney cancer.

From http://besthealthnews.com/2019/09/investigational-drug-may-offer-new-treatment-option-for-patients-with-lung-and-kidney-cancer/?utm_source=rss&utm_medium=rss&utm_campaign=investigational-drug-may-offer-new-treatment-option-for-patients-with-lung-and-kidney-cancer

from
https://healthnews010.wordpress.com/2019/09/26/investigational-drug-may-offer-new-treatment-option-for-patients-with-lung-and-kidney-cancer/